Currently, a hydrogel developed for the effective release of fibroblast growth factor-binding protein 1 (FGFBP1) inhibitors to treat pancreatic adenocarcinoma is in progress at CNR Nanotec Lecce [200]. Here, FGFBP1 is linked to pancreatic adenocarcinoma.